B. Riley Comments on Lantheus’ Q3 Earnings (NASDAQ:LNTH)

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Research analysts at B. Riley decreased their Q3 2025 earnings per share estimates for Lantheus in a note issued to investors on Thursday, March 20th. B. Riley analyst Y. Zhi now expects that the medical equipment provider will earn $1.51 per share for the quarter, down from their previous estimate of $1.57. B. Riley has a “Buy” rating and a $122.00 price objective on the stock. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million.

LNTH has been the topic of a number of other reports. Truist Financial upped their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th. JMP Securities reissued a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. Finally, The Goldman Sachs Group initiated coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $129.43.

Lantheus Price Performance

Shares of LNTH opened at $97.71 on Monday. Lantheus has a 1-year low of $57.92 and a 1-year high of $126.89. The firm has a 50 day simple moving average of $92.67 and a 200-day simple moving average of $96.51. The stock has a market cap of $6.69 billion, a price-to-earnings ratio of 16.26 and a beta of 0.38.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company’s stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,109 shares of company stock worth $6,110,806 over the last ninety days. Company insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Lantheus

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Wilmington Savings Fund Society FSB bought a new stake in Lantheus during the third quarter worth approximately $25,000. Kestra Investment Management LLC acquired a new stake in shares of Lantheus during the 4th quarter valued at $27,000. Summit Securities Group LLC bought a new stake in shares of Lantheus during the 4th quarter worth $37,000. UMB Bank n.a. grew its holdings in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after acquiring an additional 134 shares during the last quarter. Finally, Parkside Financial Bank & Trust raised its position in shares of Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock worth $76,000 after purchasing an additional 280 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.